guadecitabine + donor lymphocyte infusion

This combination therapy consists of guadecitabine (SGI-110) and donor lymphocyte infusion (DLI). Guadecitabine is a next-generation hypomethylating agent and a dinucleotide of decitabine and deoxyguanosine. It is designed to resist degradation by cytidine deaminase, thereby providing prolonged exposure to its active metabolite, decitabine. As a DNA methyltransferase (DNMT) inhibitor, guadecitabine induces DNA hypomethylation, which can lead to the re-expression of silenced tumor-associated antigens and potentially sensitize cancer cells to immune-mediated destruction. Donor lymphocyte infusion (DLI) involves the administration of T cells from the original stem cell donor to induce or enhance a graft-versus-leukemia (GVL) effect. This specific regimen is being evaluated by the M.D. Anderson Cancer Center for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) who have relapsed or are at high risk of relapse following allogeneic hematopoietic stem cell transplantation.

Other names

SGI-110 + DLIguadecitabine + DLI